EVERSANA InsightsCheckout Today’s News
Strategic PICO Planning in Oncology Markets In today’s dynamic healthcare environment, early and strategic PICO (Population, Intervention, Comparator, Outcome) planning is critical to successful evidence generation. With evolving regulatory frameworks—like the European Joint Clinical Assessment (JCA)—now leveraging PICOs to guide therapy evaluations, NAVLIN by EVERSANA® enables clients to anticipate HTA requirements, align internal stakeholders, and […]
Future-Proofing Early Development with Strategic PICO Planning A global pharmaceutical company with a diverse pipeline needed to align early clinical planning with future market access requirements—before Phase II. With Target Product Profiles (TPPs) still in development, the team turned to NAVLIN by EVERSANA® to anticipate EU Joint Clinical Assessment (JCA) expectations and build a strategic […]
Health technology assessments (HTAs) are crucial for market access and reimbursement of diagnostic innovations, yet current frameworks often fail to reflect the true value of in vivo diagnostics—such as molecular imaging (MI) tracers and contrast media (CM). These technologies are frequently assessed using methodologies designed for pharmaceuticals, resulting in inconsistent evaluations and delayed patient access […]
How one global pharma team turned fragmented pricing data into strategic power. In a complex launch environment, pricing and market access teams face mounting pressure to deliver insights that resonate with CEOs, affiliates, payers, and investors. This case study reveals how a leading oncology organization partnered with EVERSANA to overcome data silos, manual reporting, and […]
In the world of pharmaceuticals, pricing strategy becomes especially critical after the loss of exclusivity (LOE) for blockbuster drugs. Once patent protection ends, competition from generics or biosimilars floods the market, leading to significant price erosion. However, there’s an opportunity that many companies overlook: leveraging tender data to maintain a competitive edge and optimize pricing […]
Because the EU Health Technology Assessment (HTA) regulation will take effect in January 2025, pharmaceutical and medical device companies must prepare for a new era in health technology evaluations. The Joint Clinical Assessment (JCA), a core feature of the regulation (EU 2021/2282), promises a more streamlined, harmonized assessment process across Europe, particularly benefiting companies aiming […]
The pharmaceutical industry continues to face a multitude of changes that have the potential to directly impact launch strategy. From more recent tangible trends like a rise in cost-containment policies, to ongoing net price transparency forces and a focus on health equity, the potential to make mistakes during launch is growing. Reasons for traditional launch […]
The pharmaceutical industry faces a host of increasingly complex challenges and critical decisions when attempting to manage and predict their products’ plausible revenue patterns. The mishandling of revenue forecasting and evaluation can result in substantial financial liabilities, which has become more of an issue for manufacturers as products, disease states and additional factors that previously […]
EVERSANA’s Chris Lagoerio, Vice President, Revenue Management participated in a panel session, “Innovative Approaches to 340B Claims Data Identification,” at the Medicaid & Government Pricing Congress alongside fellow industry leaders Andrew Brownlee, Associate Director, Berkeley Research Group; Kathleen Black, Chairperson and Director, Government Operations, Pfizer Inc; and Cathy Burton-Meza, Senior Manager, Audits & Compliance, Gilead. […]
Pharmaceutical manufacturers commonly invest a considerable amount of time, money and additional resources into revenue management. Most would likely say they desire to invest even more because of the significant impact it has on their products’ gross-to-net. But how and where to invest valuable assets is a significant decision. The process of revenue management, including […]
How Emerging Trends are Demanding a More Holistic View to Drive Maximum Value As the complexity of investments needed to secure patient access to therapy increases, so does the impact of these investments on a company’s net revenue. Each decision needs scrutiny, not only on its own merits and how it can affect patient access […]
The case for primary market research, Real-World Data (RWD), and deep healthcare experience combined to deliver targeted market access strategies. As diseases become more complex and market access becomes more restrictive, with multiple sources of market research and data analytic solutions available, pharmaceutical executives are often overwhelmed with various sources of information. Leaders must learn […]
